BofA lowered the firm’s price target on Denali Therapeutics (DNLI) to $28 from $30 and keeps a Buy rating on the shares. The firm updated for Q4 results, cash and share count and increased its operating expense estimates in-line with recent trends.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics assumed with an Overweight at Morgan Stanley
- Denali Therapeutics: Promising Growth Prospects Despite Recent Setbacks
- Denali Therapeutics Discontinues DNL343 ALS Trial
- Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G
- Denali Therapeutics price target lowered to $35 from $38 at B. Riley
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue